annual EBITDA:
-$276.74M-$64.75M(-30.54%)Summary
- As of today (July 1, 2025), XENE annual EBITDA is -$276.74 million, with the most recent change of -$64.75 million (-30.54%) on December 31, 2024.
- During the last 3 years, XENE annual EBITDA has fallen by -$198.65 million (-254.40%).
- XENE annual EBITDA is now -2261.85% below its all-time high of $12.80 million, reached on December 31, 2013.
Performance
XENE EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly EBITDA:
-$72.08M+$4.76M(+6.20%)Summary
- As of today (July 1, 2025), XENE quarterly EBITDA is -$72.08 million, with the most recent change of +$4.76 million (+6.20%) on March 31, 2025.
- Over the past year, XENE quarterly EBITDA has dropped by -$13.62 million (-23.31%).
- XENE quarterly EBITDA is now -915.00% below its all-time high of $8.84 million, reached on September 30, 2014.
Performance
XENE quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
-$290.36M-$13.62M(-4.92%)Summary
- As of today (July 1, 2025), XENE TTM EBITDA is -$290.36 million, with the most recent change of -$13.62 million (-4.92%) on March 31, 2025.
- Over the past year, XENE TTM EBITDA has dropped by -$69.24 million (-31.31%).
- XENE TTM EBITDA is now -2130.50% below its all-time high of $14.30 million, reached on September 30, 2014.
Performance
XENE TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XENE EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.5% | -23.3% | -31.3% |
| 3 y3 years | -254.4% | -324.2% | -266.5% |
| 5 y5 years | -596.1% | -922.3% | -1005.7% |
XENE EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -254.4% | at low | -140.7% | +6.2% | -234.2% | at low |
| 5 y | 5-year | -889.5% | at low | <-9999.0% | +6.2% | -1005.7% | at low |
| alltime | all time | -2261.8% | at low | -915.0% | +6.2% | -2130.5% | at low |
XENE EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | -$72.08M(-6.2%) | -$290.36M(+4.9%) |
| Dec 2024 | -$276.74M(+30.5%) | -$76.84M(+5.3%) | -$276.74M(+9.1%) |
| Sep 2024 | - | -$73.01M(+6.7%) | -$253.59M(+8.1%) |
| Jun 2024 | - | -$68.43M(+17.1%) | -$234.53M(+6.1%) |
| Mar 2024 | - | -$58.45M(+8.9%) | -$221.12M(+4.6%) |
| Dec 2023 | -$211.99M(+66.0%) | -$53.70M(-0.5%) | -$211.36M(+5.3%) |
| Sep 2023 | - | -$53.95M(-1.9%) | -$200.70M(+8.8%) |
| Jun 2023 | - | -$55.02M(+13.0%) | -$184.52M(+15.7%) |
| Mar 2023 | - | -$48.70M(+13.2%) | -$159.44M(+24.8%) |
| Dec 2022 | -$127.74M(+63.6%) | -$43.03M(+13.9%) | -$127.74M(+16.9%) |
| Sep 2022 | - | -$37.77M(+26.2%) | -$109.27M(+25.8%) |
| Jun 2022 | - | -$29.94M(+76.2%) | -$86.89M(+9.7%) |
| Mar 2022 | - | -$16.99M(-30.8%) | -$79.22M(+1.4%) |
| Dec 2021 | -$78.09M(+179.2%) | -$24.57M(+59.6%) | -$78.09M(+18.9%) |
| Sep 2021 | - | -$15.39M(-30.9%) | -$65.65M(+11.0%) |
| Jun 2021 | - | -$22.27M(+40.4%) | -$59.15M(+60.8%) |
| Mar 2021 | - | -$15.86M(+30.7%) | -$36.78M(+31.5%) |
| Dec 2020 | -$27.97M(-29.7%) | -$12.13M(+36.5%) | -$27.97M(+4.5%) |
| Sep 2020 | - | -$8.89M(-8405.6%) | -$26.75M(+1.9%) |
| Jun 2020 | - | $107.00K(-101.5%) | -$26.26M(-26.9%) |
| Mar 2020 | - | -$7.05M(-35.4%) | -$35.94M(-9.6%) |
| Dec 2019 | -$39.76M | -$10.92M(+30.0%) | -$39.76M(+7.7%) |
| Sep 2019 | - | -$8.40M(-12.2%) | -$36.92M(-12.3%) |
| Jun 2019 | - | -$9.57M(-11.9%) | -$42.09M(+5.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$10.87M(+34.5%) | -$39.97M(+22.8%) |
| Dec 2018 | -$32.54M(+8.3%) | -$8.08M(-40.5%) | -$32.54M(+0.5%) |
| Sep 2018 | - | -$13.57M(+82.0%) | -$32.38M(+22.7%) |
| Jun 2018 | - | -$7.46M(+117.2%) | -$26.38M(-1.0%) |
| Mar 2018 | - | -$3.43M(-56.6%) | -$26.65M(-14.1%) |
| Dec 2017 | -$30.05M(+25.5%) | -$7.92M(+4.5%) | -$31.04M(+9.2%) |
| Sep 2017 | - | -$7.57M(-1.9%) | -$28.42M(+1.5%) |
| Jun 2017 | - | -$7.72M(-1.3%) | -$28.01M(+6.1%) |
| Mar 2017 | - | -$7.82M(+47.7%) | -$26.40M(+10.2%) |
| Dec 2016 | -$23.95M(+187.8%) | -$5.30M(-26.1%) | -$23.95M(+14.2%) |
| Sep 2016 | - | -$7.16M(+17.1%) | -$20.98M(+46.0%) |
| Jun 2016 | - | -$6.12M(+13.8%) | -$14.37M(+85.0%) |
| Mar 2016 | - | -$5.38M(+131.8%) | -$7.77M(-6.7%) |
| Dec 2015 | -$8.32M(-170.3%) | -$2.32M(+315.6%) | -$8.32M(+44.4%) |
| Sep 2015 | - | -$558.00K(-215.3%) | -$5.76M(-258.4%) |
| Jun 2015 | - | $484.00K(-108.2%) | $3.64M(-22.7%) |
| Mar 2015 | - | -$5.93M(-2570.8%) | $4.71M(-60.3%) |
| Dec 2014 | $11.84M(-7.5%) | $240.00K(-97.3%) | $11.84M(-17.2%) |
| Sep 2014 | - | $8.84M(+469.5%) | $14.30M(+19.1%) |
| Jun 2014 | - | $1.55M(+28.7%) | $12.01M(+14.9%) |
| Mar 2014 | - | $1.21M(-55.2%) | $10.46M(+13.1%) |
| Dec 2013 | $12.80M(-474.1%) | $2.70M(-58.9%) | $9.25M(+41.1%) |
| Sep 2013 | - | $6.55M | $6.55M |
| Dec 2012 | -$3.42M(-68.2%) | - | - |
| Dec 2011 | -$10.77M | - | - |
FAQ
- What is Xenon Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals annual EBITDA year-on-year change?
- What is Xenon Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals quarterly EBITDA year-on-year change?
- What is Xenon Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for Xenon Pharmaceuticals?
- What is Xenon Pharmaceuticals TTM EBITDA year-on-year change?
What is Xenon Pharmaceuticals annual EBITDA?
The current annual EBITDA of XENE is -$276.74M
What is the all time high annual EBITDA for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high annual EBITDA is $12.80M
What is Xenon Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, XENE annual EBITDA has changed by -$64.75M (-30.54%)
What is Xenon Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of XENE is -$72.08M
What is the all time high quarterly EBITDA for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high quarterly EBITDA is $8.84M
What is Xenon Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, XENE quarterly EBITDA has changed by -$13.62M (-23.31%)
What is Xenon Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of XENE is -$290.36M
What is the all time high TTM EBITDA for Xenon Pharmaceuticals?
Xenon Pharmaceuticals all-time high TTM EBITDA is $14.30M
What is Xenon Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, XENE TTM EBITDA has changed by -$69.24M (-31.31%)